These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32618536)

  • 21. The impact of rarity in NICE's health technology appraisals.
    Clarke S; Ellis M; Brownrigg J
    Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
    Leahy TP; Ramagopalan S; Sammon C
    BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
    Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
    Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
    Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
    Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
    Osipenko L
    BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM.
    Daly MJ; Elvidge J; Chantler T; Dawoud D
    Front Pharmacol; 2022; 13():887298. PubMed ID: 35645790
    [No Abstract]   [Full Text] [Related]  

  • 37. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Wijnen B; Witlox W; Wolff R; Fayter D; Ramaekers B; Otten T; Ryder S; Posadzki P; Worthy G; Stirk L; Armstrong N; Kleijnen J; Joore M
    Pharmacoeconomics; 2023 Jan; 41(1):33-42. PubMed ID: 36301414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
    Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ
    Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.